Applications of D-Cyclopropylalanine in Industrial Manufacturing

D-Cyclopropylalanine serves as a specialized amino acid for advanced synthesis across pharmaceutical, veterinary, and biomedical industries. Our experience as a core manufacturer ensures traceable quality in every downstream application below.

1. Antibacterial API Intermediate for Beta-Lactamase Inhibitor Synthesis

D-Cyclopropylalanine acts as a key precursor in building complex beta-lactamase inhibitor scaffolds, particularly in the synthesis of agents such as Avibactam and related diazabicyclooctane derivatives. Process chemists incorporate it during asymmetric synthesis of the cyclopropyl system, ensuring high enantiopurity critical to subsequent pharmacological activity. Manufacturers typically rely on GMP-grade input and control for potential racemization during stepwise condensation, protecting functional group orientation. Accurate in-line analytics during amidation and cyclization stages confirm the maintenance of the D-configuration before integration into the final active pharmaceutical ingredient.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP Annex 13 for API intermediates
• USP, Ph. Eur. monographs for process control
• FDA 21 CFR Part 211 quality systems

Typical usage ratio

• 0.8–1.2 molar equivalents per batch, adjusted to desired yield and impurity thresholds
• Precise ratio control based on downstream cyclization chemistries

Downstream process integration

• Integrated post-chiral resolution prior to core coupling reaction
• Applied in solution-phase or solid-phase peptide synthesis segments
• Direct use in parallel synthesis during lead compound development

Final product types

• Beta-lactamase inhibitor APIs (e.g. Avibactam, Relebactam)
• Fixed-dose antibiotic combination therapies
• Crude and purified API bulks for regulatory submission
• Sterile injectable drug formulations

2. Peptidomimetic Drug Development

D-Cyclopropylalanine provides a constrained structural motif to peptidomimetic analogues, improving receptor selectivity and in vivo stability. Research and production teams incorporate it via automated peptide synthesizers, optimizing coupling chemistry to insert cyclopropyl residues within pharmacophore designs. Analytical validation monitors the stereochemical integrity at every stage, as regulatory filings require robust characterization. The precision placement of this cyclopropane ring influences molecular interactions in protease inhibitors and specialty receptor modulators, with precise purification steps to isolate the desired enantiomer.

Industry compliance standards

• USP General Chapter <825> for compounding
• EMA ICH Q11 for API development
• GLP/GMP guidelines on peptide manufacturing
• ISO 13485 for medical device peptides

Typical usage ratio

• 1–3 mol% relative to peptide chain length, depending on desired biological profile
• Adjusted following SAR screening data and downstream analytical yield

Downstream process integration

• Installed during chain elongation in peptide reactors
• Enter N- or C-terminal amidation steps
• Post-purification using RP-HPLC or UPLC-MS validation

Final product types

• Protease inhibitor API candidates
• Peptide-based drug conjugates
• Custom research-grade peptidomimetic libraries
• Growth hormone and metabolic disorder pharmaceuticals

3. Veterinary Active Ingredient Production

Leading veterinary pharmaceutical producers use D-Cyclopropylalanine to synthesize anti-infectives for livestock and companion animals. It enters proprietary chemical transformations to generate non-hydrolyzable enzyme-targeting molecules where cyclopropyl substitution confers metabolic stability. Veterinary GMP protocols govern sourcing, batch qualification, and traceability of amino acid input, especially for injectable suspensions or oral solution products. Synthesis steps demand high-purity grades to mitigate cross-contamination in multipurpose manufacturing facilities.

Industry compliance standards

• VICH GL10 GMP for veterinary drug API
• US FDA 21 CFR Part 558 for medicated feeds
• European Pharmacopoeia 9.0 for veterinary APIs
• OIE Terrestrial Manual for veterinary medicinal products

Typical usage ratio

• 1.0–1.5 molar equivalents in target synthesis steps
• Adjusted based on seasonal demand cycles and species-specific formulations

Downstream process integration

• Introduced as a building block during API synthesis under cGMP
• Monitored by LC-MS during batch release for chiral purity
• Pre-dosed for premix or feed additive formulation

Final product types

• Injectable veterinary antibiotics
• Oral suspension veterinary anti-infectives
• Feed additive premixes
• Companion animal prescription drugs

4. Biomedical Diagnostic Reagent Synthesis

D-Cyclopropylalanine forms part of custom reagent solutions for in vitro diagnostic (IVD) test kits, particularly for enzyme-binding or protease-detection systems. Quality control requires strict screening for residual solvents and heavy metal content. Production engineers add the raw material at precursor coupling or side-chain modification stages, leveraging its chirality to enhance assay specificity. Final purification and lyophilization steps guarantee reagent stability throughout typical IVD shelf life and transport conditions.

Industry compliance standards

• ISO 13485:2016 for IVD reagent manufacturing
• CLSI EP06-A guidelines for linearity
• FDA QSR 21 CFR Part 820 for medical devices
• CE mark requirements under IVDR (EU) 2017/746

Typical usage ratio

• 0.1–0.5% w/w in final IVD test reagent brew
• Ratio set by assay sensitivity and batch scale

Downstream process integration

• Dosed in automated solution preparation for test kit components
• Used for conjugation during enzyme/protein labeling steps
• Stabilized through controlled lyophilization

Final product types

• Protease activity assay kits
• Medical diagnostic marker panels
• Enzyme-linked immunoassay reagents
• OEM-labeled clinical analyzer cartridges